New hope for tough psoriasis cases: bimekizumab steps in
NCT ID NCT06336343
First seen Nov 20, 2025 · Last updated May 20, 2026 · Updated 25 times
Summary
This study looked at whether bimekizumab can safely and effectively treat moderate-to-severe plaque psoriasis in adults who did not get better with similar drugs (IL-17 or IL-23 blockers). Bimekizumab works by reducing inflammation in the body. The goal was to see if it could clear most of the skin symptoms. About 60 people took part, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, 08520, United States
Conditions
Explore the condition pages connected to this study.